The goal of this longitudinal observational study is to understand the trajectory of Quality of Life (QoL) recovery in women with cervical cancer who have received definitive radiation therapy. The main questions it aims to answer are:

Do functional domains, such as physical, role, and social functioning, show significant and sustained improvement over the 12 months following treatment? How does the burden of treatment-related symptoms, including fatigue, nausea, and cervical cancer-specific symptoms, resolve during the one-year recovery period? Researchers will analyze changes in QoL scores over time to identify which clinical factors-such as time elapsed since treatment and baseline disease stage-serve as the most significant predictors of a patient's overall well-being.

Participants will:

• Complete standardized Quality of Life assessments using the EORTC QLQ-C30 and the cervical cancer-specific QLQ-CX24 instruments.
• Provide data at six specific intervals: baseline (pre-treatment) and at 1, 3, 6, 9, and 12 months post-radiotherapy.
• Report on multiple functional scales, including physical, role, emotional, cognitive, and social status.
• Monitor and report symptom levels for various issues such as fatigue, pain, nausea, and sexual/vaginal functioning.

This study investigates the longitudinal recovery trajectory and clinical predictors of Quality of Life (QoL) and vaginal morbidity in patients with cervical cancer following definitive radiation therapy. While combined External Beam Radiation Therapy (EBRT) and Intracavitary Radiation Therapy (ICRT/Brachytherapy) are highly effective for cancer control, they frequently lead to long-term physical sequelae, most notably radiation-induced vaginal stenosis and contraction. These changes can significantly impair sexual function and overall patient well-being.

Study Objectives and Design The research utilized a longitudinal design to track a cohort of 67 patients (mean age 51·75 ± 13·23 years) over a 12-month period. The primary objectives were to identify the clinical factors that predict the recovery of functional QoL domains.

Patients were assessed at six distinct time points: baseline (pre-treatment) and at 1, 3, 6, 9, and 12 months post-radiotherapy. QoL was measured using standardized instruments, including the EORTC QLQ-C30 (general health and functioning) and the EORTC QLQ-CX24 (cervical cancer-specific symptoms).

Clinical Predictors of Recovery

The study identifies several key independent variables that serve as predictors for post-treatment outcomes:

Time Post-Treatment: Time is a highly significant predictor for nearly all QoL domains. Acute symptoms (such as nausea, diarrhea, and fatigue) typically show the most dramatic improvement within the first 1 to 3 months.

Functional Stabilization: Functional domains, including physical and role functioning, show progressive improvement and typically peak and stabilize by the 6-to-12-month mark. Global QoL scores generally reach their highest stable levels (median 83·33) by 6 months post-treatment.

Baseline Clinical Factors: Factors such as clinical stage (with Stage IIIC1 being the most prevalent at 28·79%) and tumor extension to the upper vagina (present in 61·19% of the cohort) influence the starting QoL scores and the overall slope of the recovery curve.

Symptom Resolution and Functional Gains

Longitudinal analysis revealed significant improvements across multiple QoL metrics compared to baseline:

Symptom Burden: Scores for Fatigue, Nausea/Vomiting, and Diarrhea decreased significantly across all follow-up time points (P<0⋅001).

Functional Domains: Significant gains were sustained in Physical, Role, and Social functioning beginning as early as 1 to 3 months post-treatment.

Cervical Cancer-Specific Symptoms: The specific symptom burden (QLQ-CX24) dropped sharply and remained low throughout the year. Sexual function and vaginal aspect scores showed significant improvements later in the recovery process, specifically between 6 and 12 months.

In conclusion, this study demonstrates that while radiation therapy causes significant initial morbidity, the recovery of QoL follows a predictable timeline influenced primarily by time and adherence to vaginal dilator therapy. The dilator acts as a critical intervention to maintain anatomical integrity while the patient's functional roles and energy levels are restored over the first year of survivorship.

Inclusion Criteria:

• A confirmed diagnosis of cervical cancer, including various histological types such as Squamous cell carcinoma (85.07%), Adenocarcinoma (13.43%), or Small cell carcinoma.
• Completion of definitive radiation therapy, specifically the combination of External Beam Radiation Therapy (EBRT) and Intracavitary Radiation Therapy (ICRT/Brachytherapy).
• Participants identified as female.
• Patients were included across clinical stages I through IV, with Stage IIIC1 being the most common (28.79%).
• Willingness to participate in a 12-month longitudinal study involving assessments at six distinct time points: baseline (pre-treatment) and 1, 3, 6, 9, and 12 months post-radiotherapy.

Exclusion Criteria:

• Presence of lesions that make it impossible to use the vaginal dilator device.
• Chronic or severe bleeding that prevents the safe or effective use of the vaginal dilator.
• Emergency medical conditions or a clinical necessity for alternative treatments following the initial radiation therapy.
• Inability to attend follow-up visits or comply with the monitoring guidelines established in the study protocol.

Additionally, the sources define discontinuation criteria for participants who have already entered the study:

• The participant requests to withdraw from the project for any reason.
• The participant receives incomplete treatment due to the progression or specific nature of the disease.

Participation in this study is restricted to individuals who self-identify as female.

This eligibility criterion is defined by the study's focus on cervical cancer and the management of post-radiotherapy complications specific to this population, such as vaginal contraction and stenosis. The clinical and demographic data for the study cohort confirm that all 67 participants were women, with assessments covering sex-specific health indicators including pregnancy history, methods of childbirth, and menopausal status. Because the primary objective is to evaluate the impact of a vaginal dilator device on maintaining anatomical integrity and improving quality of life following definitive radiation for cervical cancer, only individuals with the relevant biological and clinical profile are eligible.

The study population consists of 67 women. All participants were diagnosed with cervical cancer and had completed definitive radiation therapy, specifically a combination of External Beam Radiation Therapy (EBRT) and Intracavitary Radiation Therapy (ICRT/Brachytherapy). This cohort was followed longitudinally for 12 months post-treatment.

The study does not plan to share individual participant data (IPD) with other researchers. According to the study's formal ethical and data management protocol, all participant information is kept in a secure location (such as a locked cabinet) that is strictly inaccessible to any individuals outside the immediate research team. To further protect participant privacy, all data is converted into anonymized codes during the analysis phase so that no specific individual can be identified from the research results.

Most significantly, the protocol mandates that all information, recordings, and various records must be destroyed immediately upon the completion of the research work. These measures are implemented to ensure the highest level of confidentiality and to comply with the privacy protections promised to participants during the informed consent process.